Expression and significance of TRAF6 in rectus abdominis of gastric cancer patients

doi:10.3760/cma.j.issn.1673422X.2016.12.003

Abstract

Abstract: ObjectiveTo research the expression of tumor necrosis factor receptorassociated factor 6 (TRAF6) in rectus abdominis of gastric cancer patients and abdominal benign disease patients, and discuss the relationship between nutritional status and prognosis of gastric cancer patients with TRAF6. MethodsBiopsies of the rectus abdominis were obtained intraoperatively from 64 gastric cancer patients and 53 subjects undergoing surgery for benign abdominal diseases. The expression levels of TRAF6 mRNA and protein were assessed through quantitative real time reverse transcriptase PCR (RTQPCR) and Western blotting, and the relationships between nutritional status and prognosis of gastric cancer patients and the expression status of TRAF6 were analyzed. ResultsTRAF6 mRNA was significantly upregulated in muscle of stage Ⅰ (2.080±0.611), stage Ⅱ (2.126±0.640), stage Ⅲ (3.127±0.953), stage Ⅳ (3.289±0.734) gastric cancer compared with the control group (1.249±0.723), t=4.107, P=0.001; t=4.128, P=0.000; t=8.741, P=0.000; t=9.208, P=0.000. TRAF6 protein was significantly upregulated in muscle of stage Ⅰ (0.198±0.042), stage Ⅱ (0.209±0.051), stage Ⅲ (0.295±0.072), stage Ⅳ (0.345±0.084) gastric cancer compared with the control group (0.088±0.013), t=5.203, P=0.000; t= 5.642, P=0.000; t=9.351, P=0.000; t=9.854, P=0.000. TRAF6 was upregulated in 67.2% (43/64) of gastric cancer patients. The expression of TRAF6 in muscles of gastric cancer was associated with the percent of weight loss (χ2=12.231, P=0.000), the level of serum albumin (χ2=22.808, P=0.000) and the survival rate (χ2=3.933, P=0.047). ConclusionTRAF6 is significantly upregulated in rectus abdominis of gastric cancer, suggesting that TRAF6 may play an important role in progression and prognosis of cancer cachexia, and its overexpression suggests unfavorable prognosis.

Key words: Stomach neoplasms, Rectus abdominis, Cachexia, Tumor necrosis factor receptorassociated factor 6

Qian-Xiao-Yu, TANG Jian, XU Yan, LI Lin, SUN Yuan-Shui. Expression and significance of TRAF6 in rectus abdominis of gastric cancer patients[J]. Journal of International Oncology, 2016, 43(12): 892-895.

References

［1］ Miller BS, Ignatoski KM, Daignault S, et al. Worsening central sarcopenia and increasing intraabdominal fat correlate with decreased survival in patients with adrenocortical carcinoma［J］. World J Surg, 2012, 36(7): 15091516. DOI: 10.1007/s0026801215815. ［2］ Mueller TC, Bachmann J, Prokopchuk O, et al. Molecular pathways leading to loss of skeletal muscle mass in cancer cachexiacan findings from animal models be translated to humans?［J］. BMC Cancer, 2015, 16(1): 75. DOI: 10.1186/s1288501621218. ［3］ Yang WL, Wang J, Chan CH, et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation［J］. Science, 2009, 325(5944): 11341138. DOI: 10.1126/science.1175065. ［4］ Kumar A, Bhatnagar S, Paul PK. TWEAK and TRAF6 regulate skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care, 2012, 15(3): 233239. DOI: 10.1097/MCO.0b013e328351c3fc. ［5］ Pruznak AM, Nystrom J, Lang CH. Direct central nervous system effect of alcohol alters synthesis and degradation of skeletal muscle protein［J］. Alcohol Alcohol, 2013, 48(2): 138145. DOI: 10.1093/alcalc/ags113. ［6］ Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus［J］. Lancet Oncol, 2011, 12(5): 489495. DOI: 10.1016/S14702045(10)702187. ［7］ Muscaritoli M. Targeting cancer cachexia: we′re on the way［J］. Lancet Oncol, 2016, 17(4): 414415. DOI: 10.1016/S14702045(16)000851. ［8］ Cohen S, Brault JJ, Gygi SP, et al. During muscle atrophy,thick,but not thin, filament components are degraded by MuRF1dependent ubiquitylation［J］. J Cell Biol, 2009, 185(6): 10831095. DOI: 10.1083/jcb.200901052. ［9］ Shi CS, Kehrl JH. TRAF6 and a20 regulate lysine 63linked ubiquitination of beclin1 to control TLR4induced autophagy［J］. Sci Signal, 2010, 3(123): ra42. DOI: 10.1126/scisignal.2000751. ［10］ Sun YS, Ye ZY, Qian ZY, et al. Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of gastric cancer patients［J］. 2012, 31: 81. DOI: 10.1186/175699663181. ［11］ Paul PK, Gupta SK, Bhatnagar S, et al. Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice［J］. J Cell Biol, 2010, 191(7): 13951411. DOI: 10.1083/jcb.201006098.

[1]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[2]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[3]	Xie Shuping, Sun Yahong, Wang Chao. Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 157-165.
[4]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[5]	Shao Huifang, Wang Xuehong, Lu Yongfu. Mechanism of action and clinical significance of CST1 in the progression of gastric cancer [J]. Journal of International Oncology, 2023, 50(8): 489-492.
[6]	Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu. Level of serum FABP1 and its relationship with Helicobacter pylori infection in patients with gastric cancer [J]. Journal of International Oncology, 2023, 50(6): 336-341.
[7]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207.
[8]	Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen. Correlation between blood lipid level and gastric cancer [J]. Journal of International Oncology, 2023, 50(3): 183-185.
[9]	Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen. Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 112-116.
[10]	Yang Jun, Li Rong, Zeng Jianchang. Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 82-86.
[11]	Deng Lili, Duan Xingyu, Li Baozhong. Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma [J]. Journal of International Oncology, 2023, 50(12): 751-757.
[12]	Li Jiayi, Wang Yue, Shang Lanlan, Xu Xing, Zhao Yan. Practice and prospect of artificial intelligence in diagnosis and treatment of gastric cancer [J]. Journal of International Oncology, 2023, 50(11): 677-682.
[13]	Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei. Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer [J]. Journal of International Oncology, 2023, 50(10): 631-635.
[14]	Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali. Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer [J]. Journal of International Oncology, 2022, 49(5): 276-281.
[15]	Liu Cantong, Huang Xinyi, Chen Liuyi, Chen Hao, Peng Yuhui, Huang Xuchun. Level and diagnostic value of serum insulin-like growth factor binding protein 7 in patients with gastric cancer [J]. Journal of International Oncology, 2022, 49(12): 724-728.